Metabolomics in Small Intestinal Bacterial Overgrowth

NCT04057560 | Unknown

• 1 other identifier: IRAS 255049
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Small intestinal bacterial overgrowth (SIBO) is a condition where a person's own good and useful germs, live in parts of the bowel where there should not be any germs. It may cause difficult tummy and bowel symptoms in a wide variety of patient groups. Increasing evidence suggests that sometimes small intestinal bacterial overgrowth can also trigger or worsen diseases which do not have any bowel symptoms at all. It is hugely under-diagnosed in clinical practice. Part of the reason for this is that current available diagnostic tests - culture of fluid sampled from the upper part of the gastrointestinal tract or breath testing, are complicated to do, difficult for the patient, and are not completely accurate. Therefore, the potential for a simple, more accurate test to revolutionise the diagnosis and aid with the treatment of this condition is immense. When it is accurately diagnosed, treatment with antibiotics can cure the patient of their tummy or bowel symptoms. Based on previous research the investigators have conducted, it is believed that it might be possible to diagnose this condition in a simpler and more accurate way by examining urine samples. This study will also investigate whether the condition could be diagnosed more accurately using a blood test, a different sort of breath test or using a mouth swab. The proposed study will be conducted at Lincoln County Hospital, in collaboration with Joseph Banks Laboratory at the University of Lincoln. Additional urine, blood, swab and breath samples from patients with and without small intestinal bacterial overgrowth, before and after antibiotic treatment to identify specific molecular markers in urine, blood and saliva samples which diagnosis small intestinal bacterial overgrowth accurately.

Conditions

Small Intestine Problem

Outcome Measures

Primary Outcomes (2)

• Metabolomic patterns in the biological samples collected from patients with SIBO

  Metabolomic patterns in the biological samples collected from patients with SIBO

  12 months

• Metabolomic patterns in the biological samples collected from patients who do and do not report an improvement in clinical symptoms following antibiotic treatment

  Metabolomic patterns in the biological samples collected from patients who do and do not report an improvement in clinical symptoms following antibiotic treatment

  12 moths

Secondary Outcomes (3)

• Changes in total Gastrointestinal Symptom Rating Scale scores in patients with SIBO before antibiotic treatment and following successful eradication of SIBO.

  12 months

• Changes in stool types in patients with SIBO before antibiotic treatment and following successful eradication of SIBO.

  12 months

• Changes in improvement in quality of life in patients with SIBO before antibiotic treatment and following successful eradication of SIBO.

  12 months

Study Arms (2)

SIBO Group

Control Group

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

All patients who are referred to Lincoln County Hospital for assessment of chronic diarrhoea will be considered eligible. They will be further assessed in a gastroenterology clinic using the inclusion and exclusion criteria

You may qualify if:

• Adults aged ≥ 18 and ≤ 50
• Absence of red flag symptoms i.e. unexplained weight loss, a palpable mass, unexplained iron deficiency anaemia or rectal bleeding
• GI symptoms which are due to possible SIBO
• Capacity to give informed consent

You may not qualify if:

• Previous GI surgery including cholecystectomy (except appendicectomy, inguinal/femoral hernia repair or Caesarean sections)
• Past history of inflammatory bowel disease, coeliac disease or pancreatic disease
• Past history of cancer (except basal cell carcinoma)
• Female patients who are pregnant
• Inability to adequately understand verbal or written information
• Inability or unwillingness to give informed consent
• Unwilling to consider taking antibiotics to treat SIBO
• Incapacity to comply with the demands of the study

Sponsors & Collaborators

• United Lincolnshire Hospitals NHS Trust: lead

Biospecimen

Retention: SAMPLES WITH DNA

serum, urine, breath and mouth swabs, Small bowel fluid

Central Study Contacts

Dennis Poon

CONTACT

07402687395; dpoon@nhs.net

Jervoise Andreyev

CONTACT

01522573672; j@andreyev.demon.co.uk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 23, 2019
• First Posted: August 15, 2019
• Study Start: November 1, 2019
• Primary Completion: September 1, 2020
• Study Completion: September 1, 2020
• Last Updated: October 29, 2019

Record last verified: 2019-10

Data Sharing

• IPD Sharing: Will not share